New Clinical Study Validates Nu.Q® NETs H3.1 as Key Marker for Sepsis Mortality Prediction

New Insights into Sepsis Management with Nu.Q® NETs H3.1

In a breakthrough study released by VolitionRx Limited, the efficacy of the Nu.Q® NETs H3.1 biomarker has been confirmed as an independent predictor of 28-day mortality in patients suffering from sepsis and septic shock. The multi-national epigenetics company, listed on NYSE AMERICAN as VNRX, detailed these compelling findings in a study involving robust clinical data from a significant cohort of 971 individuals.

Key Findings of the Study

The study's analysis is grounded on the examination of circulating H3.1 nucleosomes collected from plasma samples of the aforementioned patients as part of the SISPCT trial, recognized under Clinicaltrials.gov identifier NCT00832039. The findings, set to be published following peer review on MEDRXIV, highlight a noteworthy connection between elevated levels of Nu.Q® NETs H3.1 and increased risk of early mortality and organ dysfunction, particularly acute kidney injury (AKI).

Professor Michael Bauer of Jena University Hospital, who co-authored the paper, emphasized that these findings illustrate H3.1 nucleosomes' value in distinguishing organ dysfunction linked to sepsis. He stated, “The clear stratification of risk and independence from conventional markers suggests clinical utility.” This capability to predict a sepsis patient’s trajectory early on could revolutionize clinical practices, enabling timely interventions that might improve patient outcomes.

Clinical Implications

Dr. Andrew Retter, Chief Medical Officer at Volition Rx, expressed enthusiasm about these advancements, indicating that the results build upon years of diligent research. The Nu.Q® NETs technology stands out as a straightforward, affordable test designed to detect diseases correlated with NETosis. With the understanding that while NETs are vital to the immune response, their heightened levels can inflict tissue damage, the study posits that these insights could inform future therapeutic methodologies for sepsis—an area with critical necessity for improved diagnostic tools.

Future Directions

The promising data from this large-scale investigation not only reinforces the potential of Nu.Q® NETs H3.1 in clinical settings but also fosters ongoing discussions for licensing arrangements with major diagnostic firms. Volition is actively pursuing collaborations to introduce this innovative testing method in hospitals, which could transform sepsis treatment by facilitating early detection of the illness and, consequently, improving survival rates and overall quality of life for patients.

As Volition continues to evolve its product offerings, its commitment remains centered on developing simple, user-friendly, and cost-effective blood tests that serve a dual purpose: diagnosing life-threatening conditions and monitoring the health of patients and animals alike.

With operations based in Belgium and the U.S., as well as offices in London and Singapore, the company is poised for substantial growth in the diagnostics sector. Early detection is seen as a pivotal element capable of extending patients' lives and enhancing their quality of life.

For more detailed information on VolitionRx's innovative technology, visit www.volition.com.